Ovarian Cancer SYK -EGFR -CDC6 Pathway
Description
The graphical abstract shows ovarian cancer cells developing resistance to Carboplatin/Paclitaxel, marked by increased SYK and EGFR. This resistance involves EGFR and ERBB2 phosphorylation, activating SYK and ERK1/2-MAPK, leading to tumor growth. Combining SYK inhibitor (R406) and EGFR inhibitor (Lapatinib) inhibits CDC6 transcription, disrupts DNA replication, and induces apoptosis, effectively targeting drug-resistant ovarian cancer cells and offering a potential therapeutic strategy.
Acknowledgements
References
Get started with this template for freeDon’t start from scratch.
Create professional scientific illustrations quickly and easily, even without any design expertise
- Get started with a huge library of editable icons and templates such as common biological pathways, anatomy, or genetics.
- Create figures that effectively communicate your research in half the time using our editable icons.
- Use our PDB tool to quickly generate and customize protein structures
.gif)
